Clinical trials: Coronavirus 2019
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019…
- Trial name
- NCT04539262
- Testing
- Remdesivir (RDV)
- Where
- 28 sites in United States
- Volunteers
- 156 people
- Sponsor
- Gilead Sciences
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer
A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo
- Trial name
- NCT05437289
- Testing
- AZD7442 IM, AZD7442 IV
- Where
- 2 sites in China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
Coronavirus Disease 2019
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
- Trial name
- NCT04347239
- Testing
- Leronlimab (700mg)
- Where
- 18 sites in United States
- Volunteers
- 484 people
- Sponsor
- CytoDyn, Inc.
COVID-19
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes…
- Trial name
- NCT04828772
- Where
- 2 sites in Japan
- Volunteers
- 9,282 people
- Sponsor
- Bristol-Myers Squibb
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Covid19
Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19
This is a 2 part study where the first part (Phase 1) evaluates the safety of XVR011 and aims to identify the recommended Phase 2 dose.
- Trial name
- NCT04884295
- Testing
- XVR011
- Where
- 6 sites in Belgium, Italy and 1 more
- Volunteers
- 27 people
- Sponsor
- ExeVir Bio BV
Covid19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
- Trial name
- NCT04551898
- Testing
- BGB-DXP593
- Where
- 18 sites in United States, Brazil and 2 more
- Volunteers
- 181 people
- Sponsor
- BeiGene
Mild to Moderate COVID-19
JT001 (VV116) for the Early Treatment of COVID-19
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with mild to moderate COVID-19, at high risk for…
- Trial name
- NCT05242042
- Testing
- JT001
- Where
- 8 sites in China, Hong Kong
- Volunteers
- 381 people
- Sponsor
- Shanghai JunTop Biosciences Co., LTD
Covid19
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested…
- Trial name
- BOSS (NCT04914377)
- Testing
- TQ Formula/Tab
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novatek Pharmaceuticals
Coronavirus Disease
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
The purpose of this study is to assess safety, tolerability, preliminary efficacy, and PK of TAK-671 in participants with COVID-19.
- Trial name
- NCT04464460
- Testing
- TAK-671
- Sponsor
- Takeda
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Severe COVID-19 Pneumonia
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia
The study is a Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe Corona Virus Disease 2019（COVID-19）Pneumonia.
- Trial name
- NCT04880694
- Testing
- STC3141
- Where
- 4 sites in Belgium
- Volunteers
- 25 people
- Sponsor
- Grand Medical Pty Ltd.
Pharmacokinetics, Healthy Volunteers
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
The purpose of this study is to learn about the effect of the study medicine (called nirmatrelvir/ritonavir) on the pharmacokinetics of the medicine rosuvastatin in healthy volunteers.
- Trial name
- NCT05898672
- Testing
- Rosuvastatin, Nirmatrelvir/ritonavir
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019
Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
This is a clinical trial to evaluate the safety, PK, viral shedding and clinical effects of Pentarlandir™ UPPTA in patients with early COVID-19.
- Trial name
- NCT04911777
- Testing
- Pentarlandir™ UPPTA
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- SyneuRx International (Taiwan) Corp
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19 Pneumonia, Cough
Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)
This trial is an exploratory study, aiming to explore the preliminary efficacy and safety of Kesuting Syrup in the treatment of novel coronavirus pneumonia. It is planned to include a total of 200 cases.
- Trial name
- NCT05366231
- Testing
- Kesuting syrup, LianHuaQingWen Granules
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd